Business Wire

WA-KYMETA

15.11.2017 14:02:16 CET | Business Wire | Press release

Share
Kymeta Launches KĀLO™ Trek Across America

Redmond-based Kymeta—the communications company making good on the promise of global mobile connectivity—set out on a two-week trek across America in its connected Toyota RAV4 to provide a rigorous, real-world proving ground for its widely anticipated KĀLO™ internet service. KĀLO services will deliver a new mobile satellite internet service that will make mobile high-throughput internet access available and easy to buy. The KĀLO Trek Across America will begin in Washington, D.C. and wind through the country, covering over 7,000 miles, and culminating in a homecoming event at the Kymeta campus in Washington state on November 27.

Powered by the IntelsatOne® Flex network, Kymeta KĀLO services will provide high-bandwidth mobile satellite internet access to industries that require connectivity on the move like military, news reporting, first responders, construction, trains, buses and more. KĀLO services, when paired with Kymeta™ KyWay™ terminals and mTennau7 ASMs, will connect places and fixed and mobile platforms that have traditionally had limited or no connectivity at all.

“Kymeta is taking its connected car across the country to put the network through the paces,” said Dushyant Sukhija, SVP and General Manager, KĀLO Business Unit, Kymeta. “When launched, KĀLO mobile internet services will mark a revolutionary change in the way satellite services are purchased and supplied, making it as simple as purchasing a cell phone plan. The launch of Kymeta KĀLO services will usher in changes in the way businesses get work done: on the move, from everyday vehicles, in even the most difficult to reach industries and areas of the world.”

The KĀLO Trek Across America tells another important story: the possibility of a truly connected car is now a reality. Kymeta’s Toyota RAV4 will remain connected throughout its U.S. journey, conducting live streams and updates from the road. “As innovations in satellite connectivity come to market, such as our Intelsat EpicNG high-throughput satellites, we are unlocking new applications. Industries recognize that connected cars and other vehicles will enable new services and opportunities for increased efficiency; traditional networks can’t support that growth today,” said Mark Rasmussen, VP and General Manager, Mobility, Intelsat. “Leveraging our global IntelsatOne Flex network, our partnership with Kymeta will bring KĀLO internet services to every corner of the U.S., and eventually every region of the world. This plan aligns to our goal: make connectivity accessible to everyone, everything, everywhere, at any time. Kymeta KĀLO services are proof that connectivity can reach every industry, large and small, and be used for any application, no matter where you are, especially while you’re on the move.”

For a map of the KĀLO Trek Across America destinations, and to follow along as the team gives updates on the route home, visit KĀLO Trek online .

About Kymeta

What’s the missing link to connecting billions of people to high-speed mobile access? Antennas. And Kymeta offers the world’s only commercially viable electronically scanning satellite antennas and terminals. Kymeta antennas and terminals deliver high-throughput communications for land, sea and air, making mobile connectivity as available as a view of the sky. Plus, the world’s largest satellite operator, Intelsat, has joined forces with Kymeta to deliver KĀLO™ global access services that combine with Kymeta antennas and terminals to provide revolutionary mobile connectivity. Without Kymeta mTenna™ technology, connecting and staying connected to all those new satellites while on the move will be difficult, if not impossible.

If it moves, Kymeta will keep it connected. Anywhere.

For more information, visit kymetacorp.com and KALO.net .

Contact:

Business Inquiries for Kymeta:
Kymeta Corporation
Lisa Dreher, +1 425-658-8724
Director of Marketing
ldreher@kymetacorp.com
or
Media Inquiries for Kymeta:
The Summit Group
Amy Oliver, +1 801-990-1185
Mobile: +1 801-783-9067
PR/Content Manager
aoliver@summitslc.com

Link:

ClickThru

Social Media:

http://www.facebook.com/KymetaCorp

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Danish C-UAS Startup Shotling Raises €700K Oversubscribed Pre-Seed (Myriad-IPO CLUB-EIFO) for Anti-Drone Shotgun2.2.2026 07:35:00 CET | Press release

Shotling, a Danish defense technology startup specializing in kinetic short-range counter-UAS (C-UAS) systems, today announced the closing of a pre-seed financing round with €700K committed out of a targeted €500K. The round is led by Myriad Defense Fund, with co-investment from IPO CLUB’s Fund II America 2030, and a non-dilutive match-loan granted by EIFO, the Export and Investment Fund of Denmark, supporting Shotling’s mission to deliver rapid-fire modular shotgun systems against FPV drones and loitering munitions—as the global counter-UAS market accelerates towards $10B by 2030, with kinetic defense segment showing strong momentum (25%+ CAGR). Shotling’s rotary shotgun system provides unmatched close-range defense (50–100m) against the rapidly growing threat of kamikaze drones, combining a gatling-style design, with novel, high-capacity magazines, and firing rates up to 3,000 RPM using standard or tungsten-based 12-gauge shells. With deep expertise in weapons engineering and active

Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release

The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation

High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release

Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran

Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release

His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye